Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: LIK066
Dietary Supplement: Carbohydrate 50%
Dietary Supplement: Carbohydrate 8%
Dietary Supplement: Carbohydrate 25%
Dietary Supplement: Psyllium
Dietary Supplement: Carbohydrate 0%
Dietary Supplement: Calcium carbonate

First Posted Date: 2017-06-26

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03198767

Locations: 🇺🇸
Novartis Investigative Site, Lincoln, Nebraska, United States

Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication

Phase 2

Completed

Conditions: Peripheral Artery Disease (PAD); Intermittent Claudication

Interventions: Drug: LLG783
Drug: Placebo

First Posted Date: 2017-06-21

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 46

Registration Number: NCT03194776

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer

Phase 1

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: PDR001
Drug: bevacizumab
Drug: mFOLFOX6

First Posted Date: 2017-06-05

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT03176264

Locations: 🇬🇧
Novartis Investigative Site, Sutton, Surrey, United Kingdom

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Phase 3

Completed

Conditions: Post Menopausal Breast Cancer

Interventions: Drug: everolimus
Drug: exemestane

First Posted Date: 2017-06-05

Last Posted Date: 2020-04-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 235

Registration Number: NCT03176238

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase 1

Terminated

Conditions: Solid Tumors and Lymphomas

Interventions: Drug: MIW815
Biological: PDR001

First Posted Date: 2017-06-01

Last Posted Date: 2022-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 106

Registration Number: NCT03172936

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇭
Novartis Investigative Site, Zurich, Switzerland

and more 1 locations

Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Completed

Conditions: Acute Uncomplicated Plasmodium Falciparum Malaria

Interventions: Drug: KAF156
Drug: Coartem
Drug: Lumefantrine Solid Dispersion Formulation

First Posted Date: 2017-05-25

Last Posted Date: 2022-02-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 524

Registration Number: NCT03167242

Locations: 🇻🇳
Novartis Investigative Site, Binh Phuoc Province, VNM, Vietnam

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Salmeterol/fluticasone plus tiotropium
Drug: QVM149

First Posted Date: 2017-05-18

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1426

Registration Number: NCT03158311

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Phase 2

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: LIK066
Drug: Placebo

First Posted Date: 2017-05-15

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 29

Registration Number: NCT03152591

Locations: 🇩🇪
Novartis Investigative Site, Freiburg, Germany

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Phase 2

Terminated

Conditions: Diabetes Mellitus and Heart Failure

Interventions: Drug: LIK066
Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2017-05-15

Last Posted Date: 2019-08-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 125

Registration Number: NCT03152552

Locations: 🇬🇧
Novartis Investigative Site, Birmingham, United Kingdom

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

Phase 4

Completed

Conditions: Glaucoma

Interventions: Drug: brinzolamide 1%/brimonidine 0.2% fixed combination
Drug: Placebo
Drug: travoprost 0.004% ophthalmic solution

First Posted Date: 2017-05-12

Last Posted Date: 2019-02-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT03150160

Locations: 🇰🇷
Novartis Investigative Site, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy